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doi:10.1016/j.jmii.2011.12.009Background: It is still controversial whether carbapenem-resistant Acinetobacter baumannii
(CRAB) is an independent risk factor for mortality. This study aimed to determine the risk
factors and outcomes of patients with CRAB bacteremia, compared to those with
carbapenem-susceptible A. baumannii (CSAB) bacteremia.
Methods: This retrospective cohort study was conducted in Taipei Veterans General Hospital,
Taiwan. Patients with bacteremia due to A. baumannii during June 2002 and December 2007
were included.
Results: A total of 62 patients with CRAB and 164 with CSAB bacteremia were included. Among
these patients, the independent risk factors for acquiring CRAB bacteremia were hematolog-
ical malignancy [odds ratio (OR): 4.04; 95% confidence interval (CI): 1.29e12.70;
p Z 0.017], previous use of cefepime (OR: 2.60; 95% CI 1.11e6.08; p Z 0.028) and use of
total parenteral nutrition (OR: 3.06; 95% CI 1.12e8.39; p Z 0.029). The patients with CRAB
bacteremia had higher mortality rate than those with CSAB bacteremia. However, multivariate
analysis showed that among patients with A. baumannii bacteremia, acquisition of CRAB by
itself was not an independent risk factor for 14-day mortality. Instead, the independent factorsInfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2,
om (T.-L. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Carbapenem resistant and susceptible A. baumannii 357predicting14-day mortality were Acute Physiology and Chronic Health Evaluation (APACHE)
score > 20 (OR: 6.33; 95% CI: 2.32e17.26; p < 0.001), shock (OR: 2.68; 95% CI: 1.11e6.23;
pZ 0.025) and inappropriate antimicrobial therapy (OR: 2.14; 95% CI: 1.01e4.53; pZ 0.046).
Conclusion: Risk factors for CRAB bacteremia were hematological malignancies, previous use
of cefepime and use of total parenteral nutrition. Acquisition of CRAB itself is not a poor prog-
nostic factor for the patients with A. baumannii bacteremia.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii, the common nosocomial path-
ogen of ventilator-associated pneumonia and bloodstream
infection, is characterized by rapid development of resis-
tance to multiple classes of antimicrobials, including car-
bapenems.1,2 Carbapenems are usually the antimicrobial
agents of choice for the treatment of serious infections
caused by multidrug resistant A. baumannii.3,4 However,
carbapenem-resistant A. baumannii (CRAB) isolates have
been increasingly reported worldwide in recent years1,3,5,6
and are of great importance because there are limited
treatment options for the infected patients, which may
be associated with increased mortality.7 However, it is
still controversial whether CRAB itself confers a higher
mortality,8,9 or the higher mortality in patients with CRAB
infection is attributed to the inappropriate therapy or other
host factors, such as underlying diseases or disease severity.
In this study, we aimed to determine the risk factors and
outcome of patients with CRAB bacteremia, compared to
those with carbapenem susceptible A. baumannii (CSAB)
bacteremia.
Materials and methods
Study design and population
This retrospective cohort study was conducted in Taipei
Veterans General Hospital, Taiwan. Patients with mono-
microbial growth of A. baumannii in blood cultures
between June 2002 and December 2007 were included.
Data collection and definition
Clinical data or laboratory parameters were collected by
a standard form, in which definitions had been predefined.
The collected data included demographic characteristics,
underlying conditions, use of invasive procedures, labora-
tory results, antimicrobial therapy and clinical outcome.
A. baumannii bacteremia was diagnosed if an isolate of
A. baumannii from one or more blood cultures was
accompanied by two or more of the following conditions:
(1) fever (temperature > 38C) or hypothermia (temper-
ature < 36C); (2) tachypnea (respiratory rate > 24
breaths/min); (3) tachycardia (pulse rate > 90 beats/min);
(4) leukocytosis (white cell count > 12,000 cells/mm3); or
(5) leukopenia (white cell count < 4000 cells/mm3).8 When
a patient had more than one bacteremic episode, only thefirst episode was included. The date of the first positive
blood culture was considered the date of onset of bacter-
emia. The sources of bacteremia were defined as previously
described by Chiang et al.10 The severity of illness was
assessed by using the Acute Physiology and Chronic Health
Evaluation II (APACHE II) score.11
Comorbidity was divided into several categories as
follows: autoimmune diseases including rheumatoid
arthritis, systemic lupus erythematous and seronegative
spondyloarthropathy; and hematological malignancies
including leukemia, lymphoma and multiple myeloma.
Mechanical ventilation was defined as receiving ventilator
within 30 days before onset of bacteremia. Use of steroids
or previous antimicrobial agents was defined as those
administered within 30 days before bacteremia onset.
Neutropenia was defined as an absolute neutrophil count
<500 cells/mm3. Septic shock was defined as sepsis asso-
ciated with evidence of organ hypoperfusion, and either
a systolic blood pressure of <90 or >30 mmHg less than
baseline values, or a requirement for the use of vasopressor
to maintain blood pressure.12
Invasive procedures included central venous catheteri-
zation, catheter use for hemodialysis, Foley catheteriza-
tion, total parenteral nutrition, and mechanical ventilation.
To analyze the impact of antimicrobial resistance on
clinical outcome, the appropriateness of antimicrobial
therapy was assessed. Appropriate antimicrobial therapy
was defined if a patient received at least one antimicrobial
agent (including ampicillin/sulbactam) to which A. bau-
mannii was susceptible within 72 hours of blood culture
collection; otherwise, the antimicrobial therapy was
considered inappropriate. An exception was that mono-
therapy with aminoglycoside was considered as inappro-
priate. The 14-day mortality rate was used in the outcome
analysis, which was defined as death within 2 weeks after
the onset of bacteremia.
Phenotypic and genotypic identification of
Acinetobacter isolates
Isolates recovered from blood culture were phenotypically
identified by using the API ID 32GN system (bioMerieux,
Marcy l’Etoile, France). Those identified as Acinetobacter
calcoaceticuseA. baumannii complex were further analyzed
to genomic species level. Genomic species of A. baumannii
were identified by a multiplex polymerase chain reaction
method,13 and all the A. baumannii isolates were detected
for the presence of the intrinsic blaOxA-51-like gene by using
a previously described PCR detection method.14
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Antimicrobial susceptibility tests were performed by disk
diffusion test. Minimum inhibitory concentration of carba-
penems (imipenem and meropenem) for A. baumannii
isolates were determined by using agar dilution test. All the
tests were performed and the results were interpreted in
accordance with the Clinical and Laboratory Standards
Institute guidelines.15 Interpretation breakpoints for imi-
penem or meropenem of  4 mg/L were considered as
susceptible, 8 mg/L as intermediate resistant, and 16 mg/L
as resistant.15 Intermediate resistance was regarded as
resistance in our study.
Statistical analysis
Categorical variables were compared using the c2 test with
Yates correction or Fisher’s exact test. Continuous variables
were analyzed using the two-sample t test. A p value < 0.05
was considered statistically significant. Significant variables
in the univariate analysis were further analyzed by multi-
variate analysis. To assess the independent risk factors of
the patients associated with the development of CRAB
bacteremia and 14-day mortality of A. baumannii bacter-
emia, multivariate logistic regression analyses with Cox
proportional hazard model were performed to control the
effects of confounding factors. A survival curve was illus-
trated with the KaplaneMeier method. To compare the
univariate survival distribution among CRAB and CSAB,
a log-rank test was used. All statistical analyses were




A total of 226 patients with A. baumannii bacteremia were
included in this study. Among these patients, 62 cases were
caused by CRAB and 164 by CSAB. The characteristics of the
patients with CRAB and CSAB are listed in Table 1. The sex
distribution was similar between both groups of patients
(pZ 0.86). There was also no significant difference in mean
age among patients with CRAB or CSAB (69.6  15.8 vs.
68.5  17.6 years, p Z 0.662). One hundred and forty-five
patients stayed in the intensive care unit (ICU), including 49
(33.8%) with CRAB and 96 (66.2%) with CSAB.
Risks for acquisition of CRAB bacteremia
Compared to patients with CSAB bacteremia, results of
the univariate analysis (Table 1) showed that a greater
proportion of patients with CRAB bacteremia stayed in the
ICU (79% vs. 58.5%, p Z 0.007), but the duration of ICU
stay before bacteremia onset was similar in both groups
(22.92  22.58 vs. 20.78  36.59 days, p Z 0.71). The
length from admission to bacteremia was also similar
(35.87  33.58 vs. 28.24  43.97 days, p Z 0.217). CRAB
bacteremia more likely originated from pneumonia (59.7%
vs. 35.4%, p Z 0.002) and less from urinary tract infection(0% vs. 9.1%%, p Z 0.013). More patients with CRAB
bacteremia had autoimmune diseases (11.3% vs. 1.2%,
p Z 0.002), hematological malignancies (19.4% vs. 6.1%,
p Z 0.006) and received total parenteral nutrition (TPN)
(19.4% vs. 7.9%, pZ 0.028). Patients with CRAB bacteremia
were likely to have more severe illness as indicated by
higher APACHE score (27.90  8.56 vs. 23.52  9.89,
p Z 0.002) at bacteremia onset. More patients with CRAB
bacteremia presented with shock (22.6% vs. 9.1%,
p Z 0.013). Patients with CRAB bacteremia were more
likely to have received cefepime (33.9% vs. 13.4%,
p Z 0.01) or piperacillin/tazobactam (32.3% vs. 17.7%,
p Z 0.028) therapy before bacteremia onset. Difference
of exposure to carbapenems in both group was not statis-
tically significant (54.8% vs. 42.7%, p Z 0.137). Patients
with CRAB bacteremia were also more likely to have
received mechanical ventilation (83.9% vs. 60.4%,
p Z 0.001), insertion of central venous catheter (74.2% vs.
55.5%, p Z 0.016), femoral venous catheter for hemodial-
ysis (16.1% vs. 3.7%, p Z 0.002) and Foley catheter (83.9%
vs. 65.2%, p Z 0.01).
Compared to patients with CSRB bacteremia, multivar-
iate analysis showed that independent risk factors associ-
ated with CRAB bacteremia were hematological malignancy
[odds ratio (OR): 4.04; 95% confidence interval (CI):
1.29e12.70; p Z 0.017], previous use of cefepime (OR:
2.60; 95% CI: 1.11e6.08; p Z 0.028) and use of TPN (OR:
3.06; 95% CI: 1.12e8.39; p Z 0.029).
Antimicrobial susceptibility of isolates and
patients’ outcome
All except four of the isolates were resistant concomitantly
to imipenem and meropenem. Two of these isolates were
susceptible to imipenem but resistant to meropenem, and
two other isolates were susceptible to meropenem but
resistant to imipenem. The susceptibility pattern of other
antibiotics for CRAB and CSAB are illustrated in Table 2. The
resistance rates of amikacin, ceftazidime, ciprofloxacin,
cefepime and piperacillin/tazobactem were significantly
higher in the CRAB than CSAB group. Therapy with inap-
propriate antimicrobial agents was more often observed in
patients with CRAB bacteremia (80.6% vs. 51.2%, p < 0.
001). Carbapenem was empirically used in 34 (54.84%) and
70 (42.68%) patients with CRAB and CSAB bacteremia,
respectively. The patients with CRAB bacteremia had
a higher mortality rate than those with CSAB bacteremia,
by survival analysis (Fig. 1, log-rank test, p Z 0.015).
Prognostic factors of 14-day mortality in patients
with A. baumannii bacteremia
In the univariate analysis (Table 3), the factors associated
with 14-day mortality were acquisition of CRAB (35.5% vs.
20.7%, p Z 0.034), APACHE score > 20 (35.2% vs. 6.2%,
p < 0.001), shock (55.2% vs. 20.3%, p < 0.001), hemato-
logical malignancy (45.5% vs. 22.54%, p Z 0.035), and
inappropriate antimicrobial therapy (30.6% vs. 16.3%,
p Z 0.022). Multivariate analysis revealed that the inde-
pendent factors associated with 14-day mortality were:
APACHE >20 (OR: 6.33; 95% CI: 2.32e17.26; p < 0.001),
Table 1 Risk factors for acquisition of carbapenem resistant Acinetobacter baumannii bacteremia
CRAB (n Z 62) CSAB (n Z 164) Univariate
analysis
Multivariate analysis
p Odds ratio (95% CI) p
Characteristics
Age (years) 69.63  15.83 68.51  17.61 0.662
Male/female 47/15 127/37 0.86
ICU stay 49 (79) 96 (58.5) 0.007* 0.98 (0.39-2.42) 0.954
Duration in ICU prior to
bacteremia (days)
22.92  22.58 20.78  36.587 0.71
Length of hospital stay before
bacteremia (days)
35.87  33.58 28.24  43.97 0.217
APACHE II score > 20 50 (80.4) 95 (57.9) 0.003* 1.70 (0.70-4.12) 0.24
Source of bacteremia
Pneumonia 37 (59.7) 58 (35.4) 0.002* 1.70 (0.81-3.58) 0.16
Urinary tract infection 0 (0) 16 (9.1) 0.013* 0 0.998
Wound infection 2 (3.2) 4 (2.4) 0.667
Intra-abdominal infection 2 (3.2) 4 (2.4) 0.667
Catheter related infection 8 (12.9) 14 (8.5) 0.461
Co-morbidities
Steroid use 27 (43.5) 59 (36) 0.372
Hypertension 21 (33.9) 53 (32.3) 0.95
Chronic kidney disease 16 (25.8) 28 (17.1) 0.197
Diabetes mellitus 15 (24.2) 40 (24.4) 1
Coronary artery disease 14 (22.6) 31 (18.9) 0.666
COPD 14 (22.6) 26 (15.9) 0.324
Shock 14 (22.6) 15 (9.1) 0.013* 1.60 (0.61-4.21) 0.338
Hematological malignancies 12 (19.4) 10 (6.1) 0.006* 4.04 (1.29-12.69) 0.017*
Solid tumor 11 (17.7) 43 (26.2) 0.247
Cerebral vascular accident 11 (17.7) 33 (20.1) 0.83
Autoimmune diseases 7 (11.3) 2 (1.2) 0.002* 4.27 (0.55-32.97) 0.164
Liver cirrhosis 1 (1.6) 10 (6.1) 0.297
Neutropenia 1 (1.6) 1 (0.6) 0.474
Previous antimicrobial use
Aztreonam 1 (1.6) 5 (3) 1
Ceftriaxone 1 (1.6) 4 (2.4) 1
Ceftazidime 14 (22.6) 30 (18.3) 0.59
Ciprofloxacin 18 (29) 38 (23.2) 0.461
Amikacin 8 (12.9) 29 (17.7) 0.506
Piperacillin/tazobactam 20 (32.3) 29 (17.7) 0.028* 1.29 (0.55-2.89) 0.588
Cefepime 21 (33.9) 22 (13.4) 0.01* 2.60 (1.11-6.08) 0.028*
Ampicillin/sulbactam 23 (37.1) 42 (25.6) 0.124
Carbapenem 34 (54.8) 70 (42.7) 0.137
Invasive procedures uses
Foley catheter 52 (83.9) 107 (65.2) 0.01* 1.85 (0.69-4.99) 0.225
Mechanical ventilation 52 (83.9) 90 (60.4) 0.001* 1.53 (0.58-4.05) 0.387
CVC 46 (74.2) 91 (55.5) 0.016* 0.97 (0.41-2.33) 0.951
TPN 12 (19.4) 13 (7.9) 0.028* 3.06 (1.12-8.39) 0.029*
FVC for hemodialysis 10 (16.1) 6 (3.7) 0.002* 3.72 (0.99-13.96) 0.052
JVC for hemodialysis 2 (3.2) 2 (1.2) 0.303
Permanent hemodialysis catheter 1 (1.6) 1 (0.6) 0.474
* Statistically significant, p < 0.05.
Data are presented as mean  standard deviation or n (%).
CRABZ carbapenem resistant A. baumannii; CSABZ carbapenem susceptible A. baumannii; CIZ confidence interval; ICUZ intensive
care unit; APACHE Z acute physiology and chronic health evaluation; COPD Z chronic obstructive pulmonary disease; CVC Z central
venous catheter; TPN Z total parenteral nutrition; FVC Z femoral venous catheter; JVC Z Jugular venous catheter.
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Aztreonam 61 (98.4) 158 (96.3) 0.677
Ceftriaxone 61 (98.4) 152 (92.7) 0.12
Ceftazidime 60 (96.8) 117 (71.3) <0.001*
Ciprofloxacin 59 (95.2) 119 (72.6) <0.001*
Amikacin 58 (93.5) 105 (64) <0.001*
Piperacillin/tazobactam 50 (80.6) 93 (56.7) 0.001*
Cefepime 41 (66.1) 80 (48.8) 0.029*
Ampicillin/sulbactam 30 (48.4) 80 (48.8) 1
* Statistically significant, p < 0.05.
Data are presented as n (%).
CRAB Z carbapenem resistant A. baumannii; CSAB Z
carbapenem susceptible A. baumannii.
360 S.-T. Huang et al.shock (OR: 2.68; 95% CI: 1.11e6.23; p Z 0.025), and
inappropriate antimicrobial therapy (OR: 2.14; 95% CI:
1.01e4.53; p Z 0.046). Acquisition of CRAB by itself was
not an independent risk factor for 14-day mortality (OR:
1.03; 95% CI: 0.48e2.2; p Z 0.939).
Discussion
Some studies have compared the risk factors and outcomes
of patients with CRAB and CSAB bacteremia.8,12,16e18
However, some of these8,12,17,18 have not identified theFigure 1. Cumulative survival rate after episode of CRAB and
CSAB bacteremia. The curve was illustrated with the
KaplaneMeier method. The patients with CRAB bacteremia had
higher mortality rate than those with CSAB bacteremia
(log-rank test, p Z 0.015). CRAB Z carbapenem-resistant
Acinetobacter baumannii; CSAB Z carbapenem-susceptible
Acinetobacter baumannii.causative Acinetobacter isolates to the genomic species
level, therefore, they might have included patients infec-
ted with A. baumannii, Acinetobacter genomic species 3 or
Acinetobacter genomic species 13TU, which are undiffer-
entiated by phenotypic identification methods.19,20 Among
these three Acinetobacter genomic species, A. baumannii
is more frequently multidrug resistant,14 and may possess
higher pathogenicity.21 Therefore, the carbapenem resis-
tant and susceptible isolates could actually have belonged
to different Acinetobacter species, which would severely
complicate the comparison and compromise the conclu-
sions. To the best of our knowledge, the present study is
the largest to focus on patients with only A. baumannii
bacteremia.
In our study with a large case number, confounding
factors associated with patients’ outcome could be
adjusted. Although the patients with CRAB bacteremia had
a higher 14-day mortality rate than those with CSAB
bacteremia, we showed that patients with CRAB and CSAB
bacteremia had many different characteristics. Compared
to patients with CSAB bacteremia, those with CRAB
bacteremia had higher prevalence of immunocompromised
diseases and worse clinical condition before bacteremia,
such as autoimmune diseases, hematological malignancies
and shock episodes. They also had greater severity of illness
at bacteremia onset, as indicated by higher APACHE II score
and requirement for ICU care, and more frequently
required the support of invasive procedures, such as TPN,
mechanical ventilation, and use of central venous and
femoral venous catheters for hemodialysis and Foley cath-
eters. They had more often received broad-spectrum
antimicrobial therapy, such as cefepime and piperacillin/
tazobactam before bacteremia onset. CRAB bacteremia
more often originated from pneumonia and less from
urinary tract infection. Furthermore, as the CRAB isolates
were more often resistant to multiple classes of antimi-
crobial agents, the patients with CRAB bacteremia were
more likely to receive inappropriate therapy. All the above
characteristics found in patients with CRAB bacteremia
were likely to affect the patients’ outcome. Indeed, the
multivariate analysis showed that CRAB by itself was not an
independent factor of 14-day mortality in patients with A.
baumannii bacteremia, but the disease severity and inap-
propriate therapy were.
As a result, the identification of patients at risk of
acquisition of CRAB followed by prompt initiation of
appropriate therapy is important for those with A. bau-
mannii bacteremia. In our study, the multivariate analysis
showed that patients who had hematological malignancies
were more likely to acquire CRAB than CSAB. It has been
suggested that acquisition of resistance might lead to
a compromise in virulence and fitness of bacteria.22
Therefore, CRAB was likely to be pathogenic in those
patients who were more immunocompromised. Previous
use of cefepime was also a risk factor for acquiring CRAB. It
has been suggested that CRAB occurrence may be facili-
tated by the selection pressure of previous antimicrobial
use.23 The use of TPN was also a risk factor for CRAB
bacteremia in our study. However, the role of TPN in the
acquisition of CRAB was not clear. It remains to be inves-
tigated whether rich nutrients or the route by which TPN
was given played a more important role in the infection.





Univariate analysis Multivariate analysis
p Odds ratio (95% CI) p
Co-morbidities
Mechanical ventilation 40 (71.4) 111 (65.3) 0.495
Steroid use 23 (41.1) 63 (37.1) 0.706
Hypertension 18 (32.1) 56 (32.9) 1
ICU stay 17 (30.4) 106 (62.4) 0.409
Shock 16 (28.6) 13 (7.6) < 0.001* 2.63 (1.11-6.23) 0.025*
Coronary artery disease 14 (25) 31 (18.2) 0.365
Chronic kidney disease 14 (25) 30 (17.6) 0.312
Solid tumor 13 (23.2) 41 (24.1) 1
Diabetes mellitus 12 (21.4) 43 (25.3) 0.685
Hematological malignancies 10 (17.9) 12 (7.1) 0.035* 1.75 (0.64-4.79) 0.276
Cerebral vascular accident 9 (16.1) 35 (20.6) 0.585
COPD 8 (14.3) 32 (18.8) 0.569
Liver cirrhosis 4 (7.1) 7 (4.1) 0.472
Autoimmune diseases 4 (7.1) 5 (2.9) 0.23
Neutropenia 0 (0) 2 (1.2) 1
APACHE II score >20 51 (91.1) 94 (55.3) < 0.001* 6.33 (2.32-17.26) <0.001*
Inappropriate therapy 41 (73.2) 93 (54.7) 0.022* 2.15 (1.01-4.53) 0.046*
Carbapenem resistance 22 (39.3) 40 (23.5) 0.034* 1.03 (0.48-2.20) 0.939
* Statistically significant, p < 0.05.
Data are presented as n (%).
CI Z confidence interval; ICU Z intensive care unit; APACHE Z acute physiology and chronic health evaluation; COPD Z chronic
obstructive pulmonary disease.
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TPN to alimentary feeding is important in the prevention of
acquisition of CRAB.
As expected, disease severity such as high APCHE II score
and shock status were independently associated with poor
prognosis in patients with A. baumannii bacteremia.5,12
Besides, inappropriate therapy was also independently
associated with poor prognosis, despite A. baumannii being
regarded as a low-pathogenicity pathogen.8,16 Previously,
some studies have suggested that carbapenem resistance is
itself associated with poor prognosis.17 However, the
appropriateness of the therapy is not considered in the
analysis, which might be the real factor that contributes to
the poor patients’ outcome.
Although this study included a large number of patients
with A. baumannii bacteremia, it had the inherent limita-
tions of a retrospective study, including inconsistency of
patient care, noncomparability of the patients’ back-
ground, and variation in treatment, which might have
confounded the analysis. To ensure consistency in data
collection, a standard form was set up for the process. In
addition, multivariate analysis was performed to identify
independent factors of interest.
In conclusion, we showed that, among patients with A.
baumannii bacteremia, the independent risk factors for
CRAB bacteremia were underlying diseases with hemato-
logical malignancies, previous use of cefepime, and
receiving TPN. The APACHE score > 20, shock and inap-
propriate antimicrobial therapy were independent risk
factors for 14-day mortality among these patients. Carba-
penem resistance itself was not a risk factor of A. bau-
mannii mortality. Early identification of CRAB followed byprompt appropriate antimicrobial therapy, such as colistin
or tigecycline, may improve patient outcome.
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